STAAR Surgical Company Stock News

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction dr...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chie...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended July 3, 2026. Second Quarter 2026 Financial Overview Net sales of $93.5 million, up 111% Y/Y Net sales excluding China of $41.2 million, up 6.0% Y/Y...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that following an extensive global search, its Board of Directors (the "Board") has appointed Warren Foust as President and Chief Executive Officer and a new ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expect...